Jasper Therapeutics, Inc. (JSPR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+128.1%

$1.16

vs $0.51 price

Levered DCF

$1.43

After debt service

Piotroski score

0 / 9

Weak

Altman Z-score

-45.56

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-0.46×	-4.37×	-1.28×	-0.47×	-2.92×	-0.55×	-3.47×
P/B	8.45×	5.06×	1.05×	0.49×	1.29×	-0.49×	0.82×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.1×	-3.46×	0.03×	0.46×	-0.25×	0.05×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	2.62×	4.98×	7.19×	5.91×	10.95×	5.16×	13.63×
Debt / equity	0.3×	0.03×	0.04×	0.1×	0.04×	-0.05×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-1826.1%	-115.6%	-82.2%	-104.7%	-44.1%	90.1%	-23.6%
Return on invested capital	-338.1%	-116.0%	-82.5%	-121.4%	-42.8%	-106.9%	-18.7%
Return on assets	-211.9%	-89.2%	-67.9%	-77.9%	-32.7%	-135.6%	-18.3%
Free cash flow yield	-220.0%	-20.3%	-63.5%	-263.5%	-40.4%	-106.1%	-11.4%
Earnings yield	-216.1%	-22.9%	-78.3%	-213.9%	-34.3%	-183.9%	-28.9%
Enterprise value	$7.6M	$242M	-$1.7M	-$17M	$7.6M	-$996.8K	-$9.9M
Net debt / EBITDA	0.37×	1×	1.33×	0.94×	2.7×	0.88×	0×
Cash conversion cycle (days)	-2,150	0	0	0	0	0	0